News

The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?
Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.
Eli Lilly and Company (LLY) Gains Approval in Australia for Early Alzheimer’s Treatment
Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...